Predicting success: optimizing phase II ALS trials for the transition to phase III.
about
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Clinical Trials of Therapies for Amyotrophic Lateral Sclerosis: One Size Does Not Fit AllDo single-arm trials have a role in drug development plans incorporating randomised trials?Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection.Fixed dynamometry is more sensitive than vital capacity or ALS rating scale.
P2860
Predicting success: optimizing phase II ALS trials for the transition to phase III.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Predicting success: optimizing phase II ALS trials for the transition to phase III.
@en
type
label
Predicting success: optimizing phase II ALS trials for the transition to phase III.
@en
prefLabel
Predicting success: optimizing phase II ALS trials for the transition to phase III.
@en
P2860
P921
P1476
Predicting success: optimizing phase II ALS trials for the transition to phase III.
@en
P2093
James D Berry
Jeremy M Shefner
P2860
P356
10.3109/21678421.2013.838969
P577
2014-03-01T00:00:00Z